… cancer drug approved in May 2025. Treating … Gastrointestinal Stromal Tumors (GIST) * Dermatofibrosarcoma Protuberans (DFSP), a rare type of skin cancer Developed … at the Royal Initiative Pharmaceutical … to life-saving treatment for cancer patients …

… drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors … the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies …

Dr. Breelyn Wilky, an associate professor of medicine in the Department of Medical Oncology at the University of Colorado, Anschutz Medical Campus, explains the challenges patients with rare cancers like gastrointestinal stromal tumors (GIST) often face. …

… your diagnostic and treatment skills using the … and hyperthyroidism. Certain medications can increase chromogranin levels … immunohistochemical markers for a gastrointestinal stromal tumor include CD117 (c- … for example, the CLARINET trial (2014) — a randomized …

Panelists discuss how patient adherence to kinase inhibitors is crucial for disease control, requiring proactive adverse effect management, careful radiological monitoring, and strategies such as dose escalation to maximize treatment duration and …

… the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvSM … blockbuster drug and could set a new standard for future treatments. From … in patients with gastrointestinal stromal tumors, and APEX, a registration-directed trial of bezuclastinib …

… S. Food and Drug Administration (FDA) for bezuclastinib in … reported on bezuclastinib treatment were hair color change … gastrointestinal stromal tumors (GIST), and APEX, a registration-directed trial … company focused on developing precision therapies for …

… U.S. Food and Drug Administration for bezuclastinib in … TEAEs reported on bezuclastinib treatment were hair color change, … to file with the FDA later this year. We … with gastrointestinal stromal tumors or GIST, and APEX, a registration-directed trial of …

Video content above is prompted by the following: This OncLive Peer Exchange brings together leading sarcoma specialists to discuss cutting-edge GIST treatment strategies. The expert panel features Dr Shreyaskumar Patel, Dr Richard Riedel, Dr Priscilla …

Video content above is prompted by the following: Understanding GIST mutational patterns is fundamental for personalized treatment approaches in GIST care. Approximately 85% to 90% of GISTs are driven by gain-of-function mutations in KIT or PDGFR genes, …